Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Bomedemstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck Initiates Phase 3 Trial For Bomedemstat In Essential Thrombocythemia
    Merck Initiates Phase 3 Trial For Bomedemstat In Essential Thrombocythemia

    27 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240827883472/en

    BUSINESSWIRE
    27 Aug 2024
    Share Share
    Imago doses first subject in Phase II myelofibrosis treatment trial
    Imago doses first subject in Phase II myelofibrosis treatment trial

    22 Dec 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/imago-myelofibrosis-treatment-trial/

    CLINICALTRIALSARENA
    22 Dec 2022
    Share Share
    Imago Announces First Participant Dosed Ph 2 Study of Bomedemstat
    Imago Announces First Participant Dosed Ph 2 Study of Bomedemstat

    20 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/12/20/2577487/0/en/Imago-BioSciences-Announces-First-Participant-Dosed-in-Investigator-Sponsored-Phase-2-Study-of-Bomedemstat-in-Combination-with-Ruxolitinib-in-Myelofibrosis.html

    GLOBENEWSWIRE
    20 Dec 2022
    Share Share
    Imago BioSciences Presents Positive Data from Ongoing Ph2 Study of Bomedemstat
    Imago BioSciences Presents Positive Data from Ongoing Ph2 Study of Bomedemstat

    12 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2022/12/12/2572137/0/en/Imago-BioSciences-Presents-Positive-Data-from-Ongoing-Phase-2-Study-of-Bomedemstat-in-Essential-Thrombocythemia-at-ASH-2022.html

    GLOBENEWSWIRE
    12 Dec 2022
    Share Share
    Imago Announces 1st Participant Dosed Ph1 Study of Bomedemstat Combo Venetoclax
    Imago Announces 1st Participant Dosed Ph1 Study of Bomedemstat Combo Venetoclax

    30 Nov 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2022/11/30/2565433/0/en/Imago-BioSciences-Announces-First-Participant-Dosed-in-Investigator-Sponsored-Phase-1-Study-of-Bomedemstat-in-Combination-with-Venetoclax-in-Relapsed-Refractory-Acute-Myeloid-Leuke.html

    GLOBENEWSWIRE
    30 Nov 2022
    Share Share
    Merck bulks up in haematology, buying Imago for $1.35bn
    Merck bulks up in haematology, buying Imago for $1.35bn

    22 Nov 2022

    // PRESS RELEASE

    https://ir.imagobio.com/news-releases/news-release-details/merck-acquire-imago-biosciences-inc

    PRESS RELEASE
    22 Nov 2022
    Share Share